Introduction
Although the chemical nature of the metabolites of vitamin D has been fully characterized, their sites of production remain to be fully established. The important role of the kidney in the generation of 1, 25- 
hydroxyvitamin D, [1,25-(OH),D,] has been
shown by many laboratories [ 1-51. However, there is now substantial evidence that extrarenal sites of synthesis for both 24,25-dihydroxyvitamin D, [24, ,D,] and 1,25-(OH),D, also exist. In vitro, many tissues other than the kidney display hydroxylase activity [6-111, but animal experiments in vivo have been conflicting . Early human studies indicated that 24,25-(OH),D, was not formed in patients given either 25-hydroxyvitamin D, or radiolabelled vitamin D, [15] , but the methods used were of limited scope and were later challenged by reports of measurement of 24,25-(OH),D, in the circulation of both untreated and treated [21] anephric patients. 1,25-(OH),D, has been detected in the circulation of some anephric patients [22, 23] yet not in others [16, 18, 19, 21] .
Here we describe studies which have relied upon the application of sensitive radioimmunoassays to determine five of the polar metabolites of vitamin D,. Using these techniques we have followed the metabolism of vitamin D, in four patients on chronic haemodialysis, three of whom had been surgically nephrectomized. They were studied both before and during treatment with large daily doses of vitamin D, for up to 6 weeks, and the findings in these subjects compared with previous studies of both animals and man.
Methods

Subjects
The four patients (Table 1) who undertook this study were all awaiting renal transplantation and had all been on routine haemodialysis for at least 3 months; all except patient no. 2 had been surgically nephrectomized. Blood samples were obtained from the patients before dialysis sessions for a period of 3-4 weeks before and 3-6 weeks during daily ingestion of 40 000 i.u. of pure cholecalciferol. The blood was separated and the sera were stored at -20°C until assayed, when all the samples from individual patients were assayed together with single samples obtained from a group of healthy British adults (five male, five female, age range 22-89, mean 52, years).
Laboratory methods
Serum concentrations of calcium (corrected for albumin binding), phosphate, creatinine, urea and alkaline phosphatase were measured by automated methods, and N-terminal parathyroid hormone (n-PTH, normal range < 120 pg/ml) was determined by an immunoradiometric method [24] . Biochemical details of the patients are given in Table 1. Metabolites of vitamin D, were measured by radioassay after extraction of serum on C18 Seppaks and fractionation by high-pressure liquid chromatography (HPLC) on Zorbax-SIL (25 cm X 6.2 mm inner diameter) eluted with a ternary solvent system of hexane/methanol/isopropanol (92:4:4, by vol.) at a flow rate of 2.0 mVmin [25] .
This system separates calcidiol lactone ( 25-OHD3-lactone) and the hydroxylated metabolites of vitamin D, to baseline and resolves putative 25- [27] , and 1,25-(OH),D, by radioimmunoassay using antiserum S 11, which displays specificity towards 1-hydroxylated vitamin D metabolites [25] . The limits of detection of these assays were: 1.2 nmoVl for 25-OHD3, 0.096 nmolA for both 24,25-and 25,26- Further characterization of the metabolites was by radioimmunoassay of column eluates after fractionation of serum extracts by both straight phase (Zorbax-SIL eluted with hexane/methanol/ isopropanol, 94:3:3 by vol., at 3.0 ml/min) and reverse phase (Resolve C18 eluted with methanol/ water, 80/20 by vol., at 1.0 ml/min) HPLC. The effect of prior treatment of the extracts with sodium metaperiodate (5% by weight solution) was also tested.
Sta'tistical analysis
The results were subjected to linear regression analysis; the significance of the relationships was also examined using the Spearman test. In addition, analysis of co-variance was also performed after logarithmic transformation of the data. (Fig. 1) .
The effect of administration of cholecalciferol in all four patients is also shown in Fig. 1 . During the course of the study there was a gradual increase in the circulating concentration of all of the metabolites. By the end of the study circulating 25-OHD3 had increased sevenfold on average to range from 70 to 188 nmolA in the four patients. 24,25-(OH),D, also increased 12-fold to attain a range of 0.89-6.98 nmoV1, and 25,26-(OH),D, increased ninefold to range from 1.43 to 4.16 nmolA. 25-OHD,-lactone became detectable in all four patients, though in one patient this was only temporary. 1,25-(OH),D, was measurable in three of the four patients, ranging from 52.9 to 62.5 nmolA in these three; in the remaining patient it was undetectable throughout. Serum calcium fluctuated in these patients during the study but not outside previously observed concentrations for each of them, and no changes of n-PTH were observed.
Relationships between 25-OHD3 and the other metabolites
In order to study inter-relationships between circulating 25-OHD3 and the concentration of its metabolic products the data were divided into three sets. These were: firstly, individual measurements from the normal subjects, secondly, the data from patient no. 2 (Table 1) who still had kidney tissue in situ, and, thirdly, the pooled data from the other three, anephric patients.
There was a significant relationship between the concentration of 24,25-(OH),D, and that of 25-OHD, in all three sets of data tested by linear regression analysis (Fig. 2) . Analysis of co-variance showed that the slope of the regression was lower ( P < 0.05) in the anephric patients than in the normal subjects. The concentration of 25,26-(OH),D, was also related to that of 25-OHD3 (Fig. 3) ; in this case, the slopes were not sigdicantly different but the line was higher in the normal subjects than in those that had been nephrectomized ( P < 0.05).
No relationships were found between circulating 1,25-(OH),D, and 25-OHD3 in either the normal subjects, or in the patients when the dihydroxy metabolite was detectable in their sera. 25-OHD3-lactone was only measurable in three of the normal subjects and so no comparison was made; however, in all those samples from the patients in which it was detectable, a positive relationship with serum 25-OHD3 was found ( r = 0.68, P= < 0.05, y = 7.18-32.53x, not shown).
Characterization of metabolites
When serum obtained from one of the anephric patients at the end of the study was fractionated and the column eluate monitored throughout for binding activity, distinct peaks corresponding to reference compounds for all four metabolites, 1,25-(OH),D, being monitored using the specific radioimmunoassay (antiserum S11) and the other three metabolites using antiserum S 02282 against the relevant reference sterol (Fig. 4) . Prior treatment of further aliquots treated with sodium metaperiodate after the first HPLC column and before the second reverse phase fractionation destroyed all binding activity which had been associated with peaks corresponding to both the sera of six out of ten anephric patients who had received tritiated 25-OHD3 intravenously. Further studies by Haddad et al. [17] suggested that the production of 24,25-(OH),D, was a major route of metabolism in anephric patients, accounting for 12% of the available 25-OHD3 pool, which was itself normal in size but of slow turnover. Both of these latter studies, however, employed methods which were limited in scope and it is not clear whether the chromatographic systems which were used completely separated 24,25-(OH),D3 from 25-OHD3. Animal experiments have shown that, although 24,25-(OH),D, may not be formed outside the kidney under normal conditions, it is produced extrarenally in significant amounts when high concentrations of substrate (circulating 25-OHD3 > 1000 nmoM) are present after administration of very large doses of vitamin D, [12] .
The question of ectopic genesis of 1,25-(OH),D, in vivo is equally unclear. Although most reports of direct assay in the sera of anephric patients have failed to measure it [ 16, 18, 191 , recent studies have reported low but detectable circulating concentrations [22, 231. Similarly animal experiments give conflicting results according to the species and experimental design. Circulating 1,25-( OH),D, increases above control values in nephrectomized pigs given pharmacological doses of vitamin D, and maintained on peritoneal lavage over an 8 day period [13] . In contrast, in a re-evaluation of early experiments [2,3], DeLuca's group have shown that radiolabelled 1,25-(OH),D, is not formed in nephrectomized rats after prior administration of tritiated . However, this latter type of experiment is of an acute nature (18-20 h ) with administration of small physiological doses of 25-OHD, and so is of a very different nature to the studies presented here which were designed to increase the available pool of vitamin D in patients adapted to chronic haemodialysis.
In our patients 24,25-(OH),D, could be detected in the circulation before administration of vitamin D,, but the concentrations measured were uniformly low, although the patients all had normal circulating concentrations of 25-OHD3. When the concentration of 25-OHD3 was raised by ingestion of large amounts of vitamin D,, the circulating concentration of 24,25-(OH),D, rose in a substrate dependent manner, even in the anephric patients, though in them the rise was less than in normal subjects. The patients also produced 25,26-(oH),D, in a substrate dependent manner. This supports our earlier findings [28] indicating that significant extrarenal sites of synthesis for this metabolite are present in man. The kidney, however, may have some role to play as, for a given concentration of 25-OHD3, the measured concentration of 25,26-(OH),D, in anephric patients is slightly lower than in normal subjects.
1,25-(OH),D, was undetectable in all of the samples taken from the patients before administration of vitamin D, and remained so in one of the anephric subjects throughout the study. However, circulating concentrations within the normal range were observed in the other three patients during the study. In a similar fashion 25-OHD3-lactone was also formed after vitamin D, therapy was started. Renal synthesis of this latter metabolite has been suggested in both the pig [13] and the rat [29] , although one report has indicated extrarenal production over an acute experimental period in the rat [30] . Recently, Halloran et al. [31] have shown that administration of large oral doses of 25-OHD, to patients on haemodialysis, but still with kidney tissue in situ, results in substrate dependent increases of 24,25-(OH),D,, 25,26-(OH),D, and 1,25-(OH),D, in the circulation. They suggested that this may be due to residual renal hydroxylase activity but could not exclude extrarenal genesis of these metabolites. In the light of the results presented here it is probable that although residual renal hydroxylase activity may be present, sites outside the kidney d o indeed exist.
Validation of the techniques used was provided by the finding that the putative 24,25-(OH),D, and 25,26-(OH),D, fractions co-eluted with their reference standards in three separate HPLC systems, when monitored by radioimmunoassay, and were sensitive to vicinal hydroxyl function cleavage by treatment with sodium metaperiodate. In addition, the fractions collected as 25-OHD3-lactone and 1,25-(OH),D, also displayed co-elution in a number of systems with reference preparations and resisted periodate cleavage. Extrarenal sites of synthesis of the biologically active metabolite of vitamin D are seen thus to exist in man, but require to be driven by large amounts of substrate t o be significant. These findings may explain the clinical observation that anephric patients can respond to large doses of vitamin D.
